1. Focusing on microvascular function in heart failure with preserved ejection fraction.
- Author
-
Velollari O, Rommel KP, Kresoja KP, Lurz P, and Gori T
- Abstract
Heart failure is a prevalent global health issue. Heart failure with preserved ejection fraction (HFpEF), which already represents half of all heart cases worldwide, is projected to further increase, driven by aging populations and rising cardiovascular risk factors. Effective therapies for HFpEF remain limited, particularly due to its pathophysiological heterogeneity and incomplete understanding of underlying pathomechanisms and implications. Coronary microvascular dysfunction (CMD), characterized by structural and functional changes in the coronary microcirculation, is increasingly recognized as a significant factor in HFpEF even though the exact nature of their causal relationship is still unclear. This review explores prevalence, prognostic implications, and potential therapeutic targets for CMD in HFpEF. CMD's role in HFpEF might involve impaired coronary blood flow regulation, leading to myocardial ischemia, impaired relaxation, and/or adverse remodeling. Vice versa, increased wall stress in patients with HFpEF might elevate coronary resistances, further worsening microvascular perfusion. Finally, abnormalities in substrate metabolism might cause both CMD and HFpEF. Current treatments, including pharmacotherapy and device-based therapies, show limited success, highlighting the need for more targeted approaches. New possible therapies, such as the coronary sinus reducer device, may show promise in improving myocardial perfusion and function. However, further large-scale studies are required to elucidate the mechanistic links between CMD and HFpEF and to develop specialized treatments for distinct heart failure phenotypes., Competing Interests: Declarations. Conflict of interest: PL has received institutional fees and research grants from Abbott Cardiovascular, Edwards Lifesciences, and ReCor; has received honoraria from Edwards Lifesciences, Abbott Medical, Innoventric, ReCor, Boehringer Ingelheim, and Daiichi-Sankyo; and has stock options with Innoventric. KPK received speaker fees from Edwards LifeSciences. TG has received speaker fees and grant support from Abbott Vascular, Neovasc/Shockwave, BMS/Pfizer, Bayer, Astra Zeneca, Novartis, Therox, SMT, Insight Lifetech (not in relationship with this research). TG and PL are principal investigators of the German Centre for Cardiovascular Research (DZHK), Partner site Rhine Main. All other authors have no conflict of interest to disclose., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF